O R E T H A N 25 years of accumulating evidence strongly implicates the immune system in the pathogenesis of psoriasis, including both acquired immunity (T cells) and innate host defense (macrophages, antigen-presenting cells, and keratinocytes). Psoriasis also has a strong genetic component, but the identity of the genes involved has largely remained obscure. In a study recently published in Nature Genetics, 1 these 2 themes of psoriasisgenetics and immunology-come together in a coherent and clinically relevant way.
The genetic makeup of psoriasis is multifactorial: multiple genes and the environment conspire to increase one's risk of developing psoriasis. Like several other multifactorial autoimmune disorders, psoriasis manifests strong HLA associations. In 2006, HLA-Cw6 was found to be the likely cause of these HLA associations in psoriasis. 2 However, previous searches for psoriasis genes outside the HLA region yielded no consistent, reproducible evidence of linkage (ie, consistent transmission of a genetic marker with psoriasis through families 3 ). The same problem has been encountered in other multifactorial disorders. 4 We now appreciate that while linkage studies are very good for finding genes that make large contributions to risk, they are less powerful in multifactorial disorders, in which individual genes typically make only modest contributions to risk. In this setting, tests of association are much more powerful than tests of linkage. 5 Association studies are also easier to execute, as there is no need to collect family members. However, association studies require approximately 500 000 genetic markers to survey the genome comprehensively compared with the approximately 300 markers needed to perform a linkage scan.
With the dawning of the new millennium, sequencing of the human genome provided the needed markers. Called single nucleotide polymorphisms (SNPs), these markers represent subtle differences in the DNA code that normally exist between individuals. With the advent of the HapMap, 6 which provides a dense map of millions of SNPs, along with the development of microarraybased genotyping technologies that allow up to 1 million SNPs to be tested at once, the impossible became possible. To take advantage of these developments, in 2006 we initiated the Collaborative Association Study of Psoriasis, whose objective was to carry out a genomewide association scan. 1 In the initial scan, we tested 438 670 SNPs in 1359 psoriasis cases and 1400 healthy controls. We found significant associations at 3 genetic regions that had previously been associated with psoriasis (HLA-C, IL12B, and IL23R). 2, 7 As expected from earlier studies, 2, [8] [9] [10] HLA-C produced by far the strongest genetic signal. While its precise role in psoriasis remains unknown, it has been postulated that it may be involved in antigen presentation to CD8 ϩ T cells, whose migration into the epidermis appears to be required for the development of psoriatic lesions 11 ( Figure) . Besides HLA-C, IL12B, and IL23R, there were many other interesting signals requiring confirmation. Working with 5 additional groups in the United States, Canada, Germany, and France, we studied 18 of the most interesting genetic regions in an additional 5048 cases and 5051 controls. Seven of the 18 regions showed consistently strong association with the development of psoriasis, and 4 of the associations were novel. One of these was IL23A, which encodes the p19 subunit of the cytokine interleukin (IL)-23. This study is the first to find a disease association with IL23A in any human disorder. Notably, 2 of the previously identified psoriasis genes encode proteins that bind to p19. Figure) . Notably, one of the IL23R variants also confers risk for Crohn disease, 13 which has long been known to be clinically associated with psoriasis.
14 Moreover, 2 other reported psoriasis genetic "hotspots" contain epidermal defense genes that are highly overexpressed in psoriasis: DEFB4 (encoding human ␤-defensin 2), 15 and LCE3C/3D (encoding late cornified envelope proteins 3B and 3C). 16, 17 Antibodies targeting p40 are highly effective against psoriasis. 18 Because p40 is common to IL-12 and IL-23, anti-p40 antibodies block both cytokines. Interleukin 23 is elevated in psoriasis lesions, but IL-12 is not, 19 suggesting that IL-23 is the primary target. Biological agents targeting tumor necrosis factor (TNF) are also highly effective against psoriasis. 20 Notably, 2 of the novel genetic signals that we found are involved in the regulation of TNF signaling: TNFAIP3 and TNIP1 (Figure) . Together, the products of these genes function as a "brake" on immune responses triggered by TNF and by toll-like receptors, which recognize microbial agents through the innate immune system. Consistent with a role in the control of autoimmunity, different genetic variants near TNFAIP3 have been associated with rheumatoid arthritis and lupus. 21, 22 Given that psoriasis increases risk of myocardial infarction, 23 it is notable that Tnfaip3 influences the risk of coronary artery disease in mice. 24 These 2 genes provide novel targets for therapeutic intervention. Moreover, as our genetic toolbox of psoriasis risk markers expands, we may be able to predict which patients will respond best to various therapies and, even if imperfectly, begin to predict who is at risk for the development of skin and join disease as well as cardiovascular complications.
The final novel genetic hotspot implicates 2 "next-door neighbor" genes-IL4 and IL13-genes whose products support development of T H 2 cells. Psoriasis has traditionally been viewed as a "T H 1 disease," 25 and genetic defects in this region may help tip the normal T H 1/T H 2 balance toward T H 1. Interestingly, interferon gamma, a major product of T H 1 cells, supports the production of IL-23 by antigen-presenting cells. 26 Together, these studies link all of these psoriasis loci together in a plausible functional pathway (Figure) .
With the likely exception of HLA-Cw6, the causative genetic changes responsible for the association signals that we have observed remain to be determined. Our current efforts focus on pinpointing these lesions as well as on finding other associated regions in our current sample. However, further enrollment is critical. Our study involved approximately 6400 cases and 6400 controls. Research in other multifactorial autoimmune disorders has shown that the number of associated regions increases dramatically by a 2-to 3-fold increase in subjects. Potential participants can learn more about psoriasis genetics research in several ways. The Psoriasis Genetics Laboratory maintains a Web site (www.psoriasis.umich .edu) and a toll-free number (800-356-2840). Other resources include the Utah Psoriasis Initiative (http://uuhsc.utah.edu/psoriasis/) and the National Psoriasis Foundation (www.psoriasis.org). 
